EUVIMEDEUVIMED entdecken
Crossref

Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma

Ayse Karatug Kacar iD

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.14368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Ayse Karatug Kacar. Beteiligte Einrichtung: Faculty of Science, Department of Biology, Istanbul University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Insulinoma, Insulin-Secreting Cells, Pancreatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: The Scientific Research Project Coordination Unit of Istanbul University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulinoma INS‐1 cells are pancreatic beta cell tumors. Dinutuximab beta (DB) is a monoclonal antibody used in the treatment of neuroblastoma. The aim of this study is to investigate the effects of DB on pancreatic beta cell tumors at the molecular level. DB (Qarziba®) was available from EUSA Pharma. Streptozotocin (STZ) was used induce to cell cytotoxicity. DB was applied to the cells before or after the STZ application. KCND3, KCNN4, KCNK1, and PTHrP gene expression levels were analyzed by q‐RT‐PCR, and protein levels were analyzed by Western blotting. Analysis of glucose‐stimulated insulin secretion was performed. Ca +2 and CA19‐9 levels were determined by the ELISA kit. PERK, CHOP, HSP90, p‐c‐Jun, p‐Atf2, and p‐Elk1 protein levels were analyzed by simple WES. Decreased KCND3, KCNK1, and PTHrP protein levels and increased KCND3, KCNN4, KCNK1, and PTHrP gene expression levels were observed with DB applied after STZ application. Cell dysfunction was detected with DB applied before and after STZ application. Ca19‐9 and Ca +2 levels were increased with DB applied after STZ application. PERK, CHOP, and p‐Elk1 levels decreased, while HSP90 levels increased with DB applied after STZ application. CHOP, p‐Akt‐2, and p‐c‐Jun levels increased in the DB group. As a result, INS‐1 cells go to cell death via the ERK signaling pathway without ER stress and release insulin with the decrease of K+ channels and an increase in Ca +2 levels with DB applied after STZ application. Moreover, the cells proliferate via JNK signaling with DB application. DB holds promise for the treatment of insulinoma. The study should be supported by in vivo studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinomaInsulin-Secreting CellsPancreatic NeoplasmsHumansParathyroid Hormone-Related ProteinCA-19-9 AntigenCell DeathInsulinAntibodies, MonoclonalStreptozocinCell ProliferationApoptosis

Stichwörter der Autor:innen

ER stressERK and JNK pathwayK+ channel proteinsdinutuximab betainsulinoma

Substanzen

dinutuximabParathyroid Hormone-Related ProteinCA-19-9 AntigenInsulinAntibodies, MonoclonalStreptozocin

Autor:innen und Institutionen

  • Faculty of Science, Department of Biology, Istanbul University, Istanbul, Turkey.

ORCID-Profile: Ayse Karatug Kacar

Förderung

  • The Scientific Research Project Coordination Unit of Istanbul University

Zitieren

APA

Karatug Kacar, A. (2024). Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14368

Vancouver

Karatug Kacar A. Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14368

BibTeX
@article{KaratugKacar2024,
  author = {Karatug Kacar, Ayse},
  title = {Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.14368}
}
Kostenlos starten →